和鉑醫藥-B:2023年年報
Hebo Pharmaceutical-B (02142) issued 98,000 shares under the share award program on April 18
Heplatinum Pharmaceutical-B (02142) issued an announcement on April 18, 2024, according to November 2, 2020...
Wang Jingsong, chairman of the board of directors of Harbour BioMed (02142), promised not to reduce the company's shares for at least six months
Harbour BioMed (02142) announced that Dr. Wang Jingsong, Executive Director, Chief Executive Officer and Chairman of the Board of Directors, has voluntarily promised...
Market Cool On HBM Holdings Limited's (HKG:2142) Revenues Pushing Shares 29% Lower
The HBM Holdings Limited (HKG:2142) share price has fared very poorly over the last month, falling by a substantial 29%. For any long-term shareholders, the last month ends a year to forget by lock
Hebo Pharmaceutical-B (02142.HK) grants 8.38,000 share options and 3.105 million share awards
On April 3, 2024, Gelonghui Pharmaceutical-B (02142.HK) announced that on April 3, 2024, according to the share option plan and share award plan separately adopted by the company's shareholders on November 23, 2020, the company granted 8.310,000 share options and 3.105 million share awards to eligible participants, subject to acceptance by the grantor.
Hebo Pharmaceutical-B issued 1,713,500 shares under the share award program on April 2
Hebo Pharmaceutical-B (02142) announced that on April 2, 2024, it will issue 1,713,500 shares under the share award program.
HBM Holdings Returns to Profitability in 2023
HBM Holdings (HKG:2142) recorded a profit of $22.8 million in 2023, as opposed to a loss of $137.3 million in the previous year, according to a March. 28 filing with the Hong Kong bourse. Basic earnin
Hebo Pharmaceutical-B (02142) issued 1,713,500 shares under the share award scheme on April 2
Hebo Pharmaceutical-B (02142) announced that on April 2, 2024, it will issue 171.3 under the share award scheme...
Profit-driven value enhancement, a glimpse into the fission acceleration of Platinum Pharmaceutical-B (2142.HK)
At the National Conference this year, the government work report clearly identified “vigorously promoting the construction of a modern industrial system and accelerating the development of new quality productivity” as the top task of the government's work in 2024. Among them, the term “innovative drug” debuted and immediately sparked a buzz in the market.
Hebo Pharmaceutical-B (02142.HK) announced annual results: total revenue increased 119.9% year-on-year, achieving annual financial profit for the first time
On the evening of March 29 and March 28, Gelonghui announced its 2023 annual results with Platinum Pharmaceutical-B (02142.HK). As of December 31, 2023, Hebo Pharmaceutical had a total annual profit of US$22.76 million. This is also the first time that the company has achieved annual financial profit. During the reporting period, total revenue reached US$89.5 million, up 119.9% year on year (total revenue in 2022 was US$40.66 million). The company's revenue structure mainly included product licensing, research services and technology licensing. The increase in total revenue was mainly due to companies such as Pfizer, Cullinan Oncology, and Columbautech
Read the 2023 performance highlights of Heplatinum Pharmaceuticals (02142.HK) in one picture
On the evening of March 28, Hebo Pharmaceutical (02142.HK) announced the results for the year ended December 31, 2023. Let me take you to understand the specific results in a picture.
Press Release: Harbour BioMed Reports Full Year 2023 Financial Results
Harbour BioMed Reports Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, C
Hebo Pharmaceutical-B (02142) announced annual results. Profit attributable to shareholders of US$22.797 million turned a year-on-year loss into a profit
Hebo Pharmaceutical-B (02142) announced results for the year ended December 31, 2023, and the group obtained revenue...
HBM HOLDINGS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Hebo Pharmaceutical-B (02142.HK) will hold a board meeting on March 28 to approve the annual results
On March 13, Gelonghui Pharmaceutical-B (02142.HK) announced that the company will hold a board meeting on March 28, 2024 to consider and approve the Group's annual results for the year ended December 31, 2023, and deal with other matters.
HBM HOLDINGS-B: DATE OF BOARD MEETING
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal
HBM Holdings (HKG:2142) subsidiary Nona Biosciences signed an antibody-drug conjugate (ADC) discovery collaboration with Boostimmune to develop ADC therapy, a Tuesday filing said. Under the agreement,
Nona Biosciences Enters Into Collaboration Agreement With Boostimmune in Antibody-Drug Conjugate Development
CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from
and Platinum Pharmaceutical-B (02142): Establishing a cooperation agreement with BOOSTIMMUNE, INC. for the discovery of antibody-conjugated drugs
Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that Nona Biotech (Suzhou) Co., Ltd. (Nona Biotech), a wholly-owned subsidiary of the company, has signed an antibody-conjugated drug (ADC) discovery cooperation agreement with Boostimmune, Inc., to establish a strategic partnership for the company to develop ADC therapies. Under the agreement, Nona Biotech will supply Boostimmune with its dual, double light chain (H2L2) Harbour Mice platform to develop ADC therapies targeting novel targets. The Harbour Mice platform can generate dual,
Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) rose nearly 9%, and HBM9027 was granted clinical trial license in the US. Last year's results drastically reversed losses
Heplatinum Pharmaceutical-B (02142) rose nearly 9%. As of press release, it rose 8.94% to HK$1.95, with a turnover of HK$5,516,700.
No Data